(Q51462113)

5 April 2018

title

Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. (English)

1 reference

5 April 2018

1 reference

1 reference

Ninh M La-Beck

1

1 reference

5 April 2018

Beth A Zamboni

2

1 reference

5 April 2018

Alberto Gabizon

3

1 reference

5 April 2018

Hilary Schmeeda

4

1 reference

5 April 2018

Michael Amantea

5

1 reference

5 April 2018

Paola A Gehrig

6

1 reference

5 April 2018

William C Zamboni

7

1 reference

5 April 2018

publication date

18 May 2011

1 reference

5 April 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

5 April 2018

volume

69

1 reference

5 April 2018

issue

1

1 reference

5 April 2018

page(s)

43-50

1 reference

5 April 2018

https://scigraph.springernature.com/pub.10.1007/s00280-011-1664-2

exact match

0 references

cites work

Liposomal, nanoparticle, and conjugated formulations of anticancer agents

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1664-2

Use of liposomal anthracyclines in Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1664-2

An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1664-2

Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1664-2

Hormones and immune function: implications of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1664-2

Innate immunity in aging: impact on macrophage function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1664-2

Sex hormones and the immune response in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1664-2

Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1664-2

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1664-2

Clinical pharmacokinetics of doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1664-2

Pharmacogenetics of target genes across doxorubicin disposition pathway: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1664-2

Hormonal and immunological mechanisms mediating sex differences in parasite infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1664-2

Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1664-2

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1664-2

Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1664-2

Pharmacokinetics in older persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1664-2

10.1007/S00280-011-1664-2

21 January 2018

Identifiers

DOI

1 reference

5 April 2018

1 reference

5 April 2018